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Acute pancreatitis (AP) is a rare but life-threatening complication of SLE. The current study evaluated the clinical characteristics
and risk factors for the mortality of patients with SLE-related AP in a cohort of South China. Methods. Inpatient medical records
of SLE-related AP were retrospectively reviewed. Results. 27 out of 4053 SLE patients were diagnosed as SLE-related AP, with an
overall prevalence of 0.67%, annual incidence of 0.56‰ and mortality of 37.04%. SLE patients with AP presented with higher
SLEDAI score (21.70 ± 10.32 versus 16.17 ± 7.51, P = 0.03), more organ systems involvement (5.70 ± 1.56 versus 3.96 ± 1.15,
P = 0.001), and higher mortality (37.04% versus 0, P = 0.001), compared to patients without AP. Severe AP (SAP) patients had a
signiﬁcanthighermortalityratecomparedtomildAP(MAP)(75%versus21.05%,P = 0.014).16SLE-relatedAPpatientsreceived
intensive GC treatment, 75% of them exhibited favorable prognosis. Conclusion. SLE-related AP is rare but concomitant with high
mortality in South Chinese people, especially in those SAP patients. Activity of SLE, multiple-organ systems involvement may
attribute to the severity and mortality of AP. Appropriate glucocorticosteroid (GC) treatment leads to better prognosis in majority
of SLE patients with AP.
1.Introduction
Systemic lupus erythematosus (SLE) is a chronic, autoim-
mune, inﬂammatory disease characterized by the presence of
a plethora of autoantibodies, immune complex formation,
and multiple organ system involvement. Gastrointestinal
(GI) manifestations are common in SLE patients, but acute
pancreatitis is rare [1–6]. It was reported that 19.2%–50% of
SLE patients presented with gastrointestinal symptoms [7–
11], whereas pancreatitis occurred in about 0.7%–8.2% of
patients with SLE [7, 8, 11, 12] and the annual incidence
was approximately 0.4–1.1‰ [3–5]. Our knowledge about
SLE-related acute pancreatitis (AP) is mostly based on
individual case reports or small case series. Despite its rarity,
AP can be a life-threatening complication of SLE if not
treated appropriately. Prevalence of SLE is relatively high
in Chinese people, which is 0.7∼1/1000 in comparison to
0.51/1000 in United States [13]. But so far very few case
reports on SLE-related AP in Chinese population have been
published. The current study aims to clarify the clinical
characteristics, severity, mortality, and outcome of SLE-
related acute pancreatitis in south China.
2.MaterialsandMethods
A retrospective review of inpatient medical records between
January 2000 and January 2012 was performed at the First
Aﬃliated Hospital of Sun Yat-Sen University in South China.
4053 patients were classiﬁed as SLE during the past 12
years who fulﬁlled at least four of the American College
of Rheumatology (ACR) revised classiﬁcation criteria for
SLE (1997) [14]. A diagnosis of acute pancreatitis (AP)
was established by the presence of typical clinical symptoms
(including abdominal pain, nausea, and vomiting) and
conﬁrmed by more than a three-fold elevation of serum
amylase or lipase or evidence of imaging ﬁndings-computer
tomography [CT] scan or ultrasonography (USG) [15].
Among these SLE patients, 27 were with dual simultaneous2 Clinical and Developmental Immunology
diagnosis of AP, and another 23 age- and gender-matched
SLE patients without AP were randomly selected. Review of
the clinical ﬁles of these 50 SLE patients was performed and
data was extracted.
T h eS L ED i s e a s eA c t i v i t yI n d e x( S L E D A I )[ 16]w a su s e d
to evaluate SLE activity during AP, and patients were deﬁned
as active SLE if the SLEDAI score was equal to or greater
than 6. The Systemic Lupus International Collaborating
Clinics/ACR (SLICC/ACR) damage index [17]w a su s e dt o
ascertain organ damage in SLE. The Atlanta criteria [18]
were used to classify the severity of acute pancreatitis. Severe
acute pancreatitis (SAP) was deﬁned as the presence of at
least three of Ranson’s criteria and eight or more Acute
Physiology and Chronic Health Evaluation II (APACHE II)
score, or with the evidence of organ failure (systolic blood
pressure<90mmHg, PaO2≤60mmHg on room air, cre-
atinine>2mg/dL, gastrointestinal bleeding>500mL/24h,
DIC or severe hypocalcemia≤7.5mg/dL) or local complica-
tions (i.e., pancreatic necrosis, abscess, or pseudocyst). The
positivity of CT scan was deﬁned as diﬀuse or segmental
enlargement of the pancreas, illegibility of peripancreas fat,
low/high density area in contrast, and peripancreas eﬀusion
[19]. The positivity of USG was deﬁned as pancreatic
enlargement, decreased echodensity, and possible ﬂuid col-
lections [20].
Demographic information including gender, age at SLE
onset, duration between the onset of SLE and AP, history
of alcohol consumption, gallstone, metabolic abnormalities
(hypertriglyceridemia and hypercalcemia), clinical symp-
toms, laboratory ﬁndings, medications (especially corticos-
teroid, and immunosuppressive agents (ISA)) and outcome
were documented. Acute pancreatitis related to mechanical
obstruction (choledocholithiasis), toxic-metabolic etiolo-
gies (alcohol intake, drugs, hypercalcemia, or hypertriglyc-
eridemia), infection, or trauma were ruled out in every case
[21].
2.1. Statistical Analysis. Statistical analysis was done using
the SPSS program 13.0 and Prism software version 5.0. The
Mann-Whitney U test was used for continuous variables
and the chi-square or Fisher’s exact test for categorical
variables. Survival rates were estimated using the Kaplan-
Meier method. A P value <0.05 was considered statistically
signiﬁcant in all comparisons.
3. Results
3.1. Demographic and Clinical Characteristics of SLE-Related
Acute Pancreatitis. 27 out of 4053 SLE patients were diag-
nosed as SLE-related AP during the past 12 years, with
an overall prevalence of 0.67% and annual incidence of
0.56‰. One patient developed 2 episodes of pancreatitis
and the other 26 patients had only one episode at the time
of hospitalization. The demographic and clinical features of
each SLE-related AP patient were shown in Table 1.
3.2. Comparison of Demographic and Clinical Features in SLE
Patients with and without SLE-Related AP. The majority of
patients (92.59%, 25/27) were females and the mean age
at SLE onset was 26.96 ± 13.30 years (ranged from 14 to
57 years). Time interval between the onset of SLE and AP
r a n g e df r o m1w e e kt o2 0y e a r s ,a n dm o r et h a nh a l fo ft h e
patients (51.85%, 14/27) developed AP within the ﬁrst year
of the onset of SLE. All these 27 patients were classiﬁed as
active SLE with average SLEDAI score of 21.70 ±10.32 at the
onset of AP. The clinical features related to acute pancreatitis
in these 27 SLE patients were nonspeciﬁc. Abdominal pain
(92.59%), fever (77.78%) and nausea/vomiting (74.07%),
were the most frequent manifestations and other symptoms
includeddiarrhea(44.44%),lossofappetite(44.44%)andGI
tract hemorrhage (14.81%).
Other organ system involvement was found in all SLE-
related AP patients with an average number of 5.70 ±
1.56 (ranged from 3 to 8 organs), including hematological
system, kidney, liver, serositis, mucocutaneous involvement,
respiratory system, arthritis, and central nervous system.
Clinical features and laboratory ﬁndings were compared
between these two groups and the results were shown in
Table 2. SLE patients with AP presented with higher SLEDAI
score (21.70 ± 10.32 versus 16.17 ± 7.51, P = 0.03), more
organsysteminvolvement(5.70±1.56versus3.96±1.15,P =
0.001),higherfrequenceoffever(77.78%versus39.13%,P =
0.006), hepatological and hematological disorders (82.61%
versus 34.78%, P = 0.01; 100% versus 60.87%, P = 0.001),
serositis (62.96% versus 26.09%, P = 0.01), elevated CRP
(81.82% versus 47.62%, P = 0.02), positive anti-La antibody
(33.33% versus 0, P = 0.003), and higher mortality (37.04%
versus 0, P = 0.001) compared to SLE patients without AP.
3.3. Comparison of Clinical Features between SAP and MAP
Patients. According to Atlanta criteria, 27 SLE-related AP
patients were divided into SAP group (severe acute pan-
creatitis, n = 8, 29.63%) and MAP group (mild acute
pancreatitis, n = 19, 70.37%). The comparison of the
demographic and clinical data between SAP and MAP
patients as shown in Table 3. The results indicated that the
age of onset of AP in SAP patients as signiﬁcantly younger
than MAP (19.63 ± 10.88 versus 30.05 ± 13.25, P = 0.016).
SAP patients presented with signiﬁcantly higher mortality
(75% versus 21.05%, P = 0.014) and more abnormal
hematologic ﬁndings (thrombocytopenia and leucopenia,
100% versus 52.63%, P = 0.026; 87.5% versus 31.58%, P =
0.013, resp.) compared to MAP. The Kaplan-Meier survival
curves showed death rate within 30 days after onset of acute
pancreatitis in SAP and MAP groups (Figure 1).
3.4. Comparison of Clinical Features between Pediatric- and
Adult-Onset SLE-Related AP. SLE-related AP patients were
divided into pediatric-onset group (under 18 years of age,
n = 10) and adult-onset group (n = 17). Demographic
andclinicalcharacteristicswerecomparedbetweenthesetwo
groups. Pediatric-onset SLE-related AP had higher rate of
severe AP (60% versus 11.76%, P = 0.014), higher serum
amylase level (17.55 ± 16.09 versus 6.53 ± 5.42, P = 0.007),
lower percentage of positive anti-Ro antibody (25% versus
84.62%, P = 0.01), and lower rate of anti-La antibodyClinical and Developmental Immunology 3
Table 1: The demographic and clinical characteristics of each SLE patient with AP.
Case Age at SLE onset
(y)
Duration
between onset
of SLE and AP
(m)
SLEDAI score at
o n s e to fA P
Number of
involved organs
concomitant
with AP
GC treatment
after onset of AP Outcome
1 23 0.5 9 5 Increased dose In remission
2 16 48 12 4 Stop In remission
3 18 12 14 6 Increased dose Died
4 22 72 14 7 Increased dose In remission
5 16 36 16 7 Increased dose In remission
6 57 24 17 4 Increased dose In remission
7 36 0.5 17 6 Initial treatment Died
8 48 180 18 7 maintaining Died
9 14 36 21 4 maintaining Died
10 14 12 23 7 Increased dose Died
11 19 2 23 6 Increased dose In remission
12 14 2 27 7 Increased dose Died
13 46 1 25 4 Increased dose In remission
14 22 0.25 18 3 Decreased dose In remission
15 51 240 18 6 Decreased dose In remission
16 42 4 19 7 Increased dose In remission
17 20 84 18 5 Decreased dose Died
18 39 24 13 5 Increased dose In remission
19 15 2 33 6 Decreased dose Died
20 15 36 41 7 Increased dose In remission
21 26 3 41 8 Increased dose Died
22 39 1 27 6 Increased dose In remission
23 20 72 10 3 maintaining In remission
24 36 12 38 6 maintaining Died
25 16 2 8 3 Increased dose In remission
26 30 48 47 8 Increased dose In remission
27 14 72 19 6 maintaining In remission
0
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Figure 1: Kaplan-Meier survival curves for the time (days) from
onset of SLE-related acute pancreatitis to death.
(0 versus 53.85%, P = 0.02) compared to adult-onset SLE-
related AP. However, the diﬀerence in mortality was not
statistically signiﬁcant between pediatric and adult patients
(50% versus 29.41%, P = 0.26).
3.5. Comparison of Clinical Features between Mortality and
NonmortalitySLEPatientswithAP. Theriskfactorsformor-
tality were further analyzed. 27 SLE-related AP patients were
divided into mortality group (n = 10) and nonmortality
group (n = 17). The clinical manifestations were compared
between these two groups and shown in Table 4.T h e
mortality group had higher percentage of hypoalbuminemia
(90% versus 47.06%, P = 0.031), hyperbilirubinemia (40%
versus 5.88%, P = 0.047), hematuria (100% versus 41.18%,
P = 0.002), and granular casts (70% versus 23.53%, P =
0.024) compared to nonmortality group. Severity of acute
pancreatitis was the most powerful risk factor for mortality
in SLE-related AP (OR 11.25, 95% CI (1.611, 78.57) and
P = 0.014).4 Clinical and Developmental Immunology
Table 2: Comparison of demographic and clinical features in SLE patients with and without AP.
S L Ew i t hA P( n = 27) SLE without AP (n = 23) P
Female (%) 25 (92.59%) 20 (86.96%) 0.42
Age on SLE diagnosis (y) 26.96 ±13.30 28.39 ±9.98 0.26
GCs dose (mg) 61.19 ±37.63 50.96 ±28.82 0.18
SLEDAI score 21.70 ±10.32 16.17 ±7.51 0.03
SLICC/ACR damage index 1.19 ±0.92 0.96 ±1.19 0.11
Mortality 10 (37.04%) 0 0.001
Fever (%) 21 (77.78%) 9 (39.13%) 0.006
Neuropsychiatric (%) 7 (25.93%) 1 (4.35%) 0.042
Pulmonary (%) 11 (40.74%) 5 (21.74%) 0.13
Articular (%) 16 (59.26%) 16 (69.57%) 0.32
Mucocutaneous involvement (%) 18 (66.67%) 16(69.57%) 0.54
Renal (%) 24 (88.89%) 20 (86.96%) 0.59
Hepatological (%) 19 (82.61%) 8 (34.78%) 0.01
Hematological (%) 27 (100.00%) 14 (60.87%) 0.001
Serositis (%) 17 (62.96%) 6 (26.09%) 0.01
Number of organs involved 5.70 ±1.56 3.96 ±1.15 0.001
Positive anti-dsDNA (%) 24 (88.89%) 19 (82.61%) 0.41
Positive anti-Sm (%) 6/21 (28.57%) 10 (43.48%) 0.24
Positive anti-Ro (%) 13/21 (61.90%) 14 (60.87%) 0.60
Positive anti-La (%) 7/21 (33.33%) 0 0.003
Positive ACL-IgG (%) 4/21 (19.05%) 1/22 (4.55%) 0.168
Positive ACL-IgM (%) 4/21 (19.05%) 1/22 (4.55%) 0.16
Positive anti-β2 GPI (%) 3/21 (14.29%) 2/22 (9.09%) 0.48
Low C3 (%) 26/26 (100%) 22 (95.65%) 0.47
Low C4 (%) 21/26 (80.77%) 20 (86.96%) 0.42
Elevated CRP (%) 18/22 (81.82%) 10/21 (47.62%) 0.02
4. Treatment and Outcome
Among these 27 SLE-associated AP patients, 26 were on
steroid treatment before the onset of AP and the average
dosage of GCs was 61.19 ± 37.63mg/day (ranged from
10mg/day to 120mg/day). AP was considered as the initial
presentation of SLE in one patient (patient 7 in Table 1), and
standard GC treatment started after diagnosis. Additional
immunosuppressive agents (ISA) were also administrated
in 22 patients before the onset of AP, including 18
on hydroxychloroquine, 2 azathioprine, 8 methotrexate, 5
cyclophosphamide, and 1 FK506. After the episodes of AP,
oralmedicineswerestoppedbecauseoffasting.Methotrexate
or cyclophosphamide were continuously prescribed in 5
patients but switched to I.V. injection. 1 patient developed
recurrentepisodeofAPwhenincreasingthedosageofGCfor
the relapse of SLE, and GC treatment was stopped (patient
2) after onset of AP. 25 patients were continuously treated by
GCs and/or ISA during their episode of AP. 16 patients were
given aggressive treatment of GCs and/or ISA (12 patients
obtained clinical and laboratory improvement (75%) and
4 died), 5 patients were treated with the maintenance dose
of GCs and/or ISA (2 patients in remission (40%) and 3
died), and 4 patients were treated with decreased dose of
GCs because of fever and concerning of potential infections
(2 patients in remission (50%) and 2 died) (The results
showed in Figure 2). Totally, 10 patients died and the overall
mortality rate was 37.04% (10/27).
5. Discussion
SLE-related AP is relatively rare compared to other organ
injury involved in lupus. The incidence of clinical AP
associated with SLE varies from 0.7 to 4% [5, 8, 12, 22],
with the annual incidence of 0.4–1.1‰ [3, 4]. Most previous
studies on this issue were individual case reports or small
case series. So far, the Hopkins lupus cohort [12]r e p o r t e d
the largest case series with 63 SLE-attribute pancreatitis out
of 1740 SLE patients (3.5%), and a Taiwan series reported
40 out of 2976 SLE patients (1.34%). This study was the
ﬁrst report of the SLE-related AP in south China. In current
cohort, 27 out of 4053 SLE patients were diagnosed as
SLE-related AP, with the prevalence of 0.67%, and annual
incidence of 0.56‰, which is comparable with the ﬁndings
of previous literatures [3–5, 8, 12, 22].
The pathogenic mechanism of SLE-related AP is very
complex and multifactors. Vascular damage (including vas-
culitis, intimal thickening, immune complex deposition,
occlusion of arteries, and arterioles), autoantibody produc-
tion, abnormal cellular immune response, and drug toxicity
may be responsible for the development of pancreatitis [8].Clinical and Developmental Immunology 5
Table 3: Comparison of demographic and clinical characteristics between SLE-related severe acute pancreatitis (SAP) and mild acute
pancreatitis (MAP).
SAP (n = 8) MAP (n = 19) P value
Demographic characteristics
Female 7 (87.50%) 18 (94.74%) 0.513
Age of onset AP (y) 19.63 ±10.88 30.05 ±13.25 0.016
Interval between onset of SLE and AP (m) 23.38 ±28.25 44.36 ±64.73 0.822
Early AP (1 year) 5 (62.50%) 9 (47.37%) 0.678
SLEDAI score at onset of AP 22.13 ±6.24 21.53 ±11.77 0.44
SLICC/ACR damage index 1.25 ±0.89 1.16 ±0.96 0.854
Number of organs involved 5.75 ±1.28 5.68 ±1.70 0.893
Intensive therapy of GC/ISA 5 (62.50%) 11 (57.89%) 1
Mortality 6 (75%) 4 (21.05%) 0.014
Clinical characteristics
Fever 8 (100.00%) 13 (68.42%) 0.136
Mucocutaneous involvement 6 (75.00%) 12 (63.16%) 0.676
Articular involvement 3 (37.50%) 10 (52.63%) 0.678
Serositis 5 (62.50%) 10 (52.63%) 0.696
Neuropsychiatric involvement 2 (25.00%) 5 (26.32%) 1
Renal involvement 7 (87.50%) 15 (78.95%) 1.0
Laboratory ﬁndings
Serum amylase∗ 18.09 ±18.15 7.46 ±5.88 0.077
Serum lipase∗ 8.53 ±3.14 7.63 ±5.45 0.616
Elevated serum transaminase 7 (87.5%) 11 (57.89%) 0.201
Thrombocytopenia 8 (100%) 10 (52.63%) 0.026
Leucopenia 7 (87.50%) 6 (31.58%) 0.013
Positive anti-dsDNA 8 (100.00%) 16 (84.21%) 0.532
Positive anti-Sm 1/7 (14.29%) 5/14 (35.71%) 0.613
Low C3 8/8 (100.00%) 18/18 (100.00%) 1
Low C4 7/8 (87.50%) 14/18 (77.78%) 1
Anti-Ro 2/7 (28.57%) 11/14 (78.57%) 0.056
Anti-La 1/7 (14.29%) 6/14 (42.86%) 0.337
∗Times in excess of the upper limit of normal (ULN).
In the current cohort, more than half patients (51.85%)
developed acute pancreatitis within 1 year of the onset of
SLE, and all 27 patients were active SLE with dramatically
elevated SLEDAI scores and other simultaneous SLE mani-
festations, especially the hematologic and renal involvement.
SLE patients with AP presented with higher SLEDAI scores
compared to patients without AP. Previous studies [3, 4,
22, 23] also demonstrated that episodes of SLE-related
pancreatitis signiﬁcantly increased in the active SLE group.
APwasconsideredasoneoftheclinicalfeaturesofactiveSLE
andwasassociatedwiththeactivityofthediseaseitself.These
results indicated that SLE itself can be the primary etiologic
factor or cofactor predisposing to AP.
SLICC/ACR damage index score represents disease bur-
den in SLE patients. It was signiﬁcantly higher in SLE
patients with pancreatitis compared to SLE patients without
pancreatitis in Hopkins cohort [12]. Although SLE-related
AP had more organ system involvement in current study, the
damage index score was low, and there was no signiﬁcant
diﬀerence between SLE patients with and without AP (1.19±
0.92 versus 0.96 ± 1.19, P = 0.11). The reason of the
low-damage index score might lie in the relatively younger
onsetage,shorterdurationofdisease,andless-chronicorgan
damage.
Our study found that pediatric-onset AP tended to
be more severe compared to adult-onset AP. SAP group
had signiﬁcant higher prevalence of thrombocytopenia and
leucopenia than MAP group. Mortality patients has higher
rate of hypoalbuminemia, hematuria, granular casts, and
hyperbilirubinemia than nonmortality group, which indi-
cated that multiple organ systems involvement, especially
hematological, renal, and liver injury in SLE patients might
be the major causes due to the severity and mortality of
AP. In general population, the mortality rate of AP is about
3.8%∼10% [24–27]. Approximately 15∼20% of all AP cases
were SAP which accounted for a mortality rate of 16.3%∼
30% [27–29]. SLE-related AP patients had much higher
mortality. Wang et al. [23] reported that the mortality rate
was 27.5% in all SLE-related AP and 78.57% in SAP. Richer
et al. [30] reported that 57% of childhood-onset lupus with
pancreatitis developed SAP with the mortality of 45%. In
our cohort, the overall mortality rate of SLE-related AP was6 Clinical and Developmental Immunology
Table 4: Comparison of demographic and clinical characteristics between mortality and non-mortality group.
Mortality
(n = 10)
Non-mortality
(n = 17) P value
Demographic characteristics
Female 10 (100%) 15 (88.24%) 0.387
Age of onset AP (y) 24.10 ±12.02 28.65 ±14.07 0.123
SLEDAI score at onset of AP 25.00 ±9.40 19.76 ±10.61 0.065
Number of organs involved 6.20 ±1.14 5.41 ±1.73 0.167
Intensive therapy of GC/ISA 4 (40%) 12 (70.59%) 0.124
Clinical characteristics
Fever 10 (100%) 11 (64.71%) 0.042
Mucocutaneous involvement 6 (60%) 12 (70.59%) 0.439
Articular involvement 6 (60%) 7 (41.18%) 0.293
Serositis 7 (70%) 8 (47.06%) 0.226
Neuropsychiatric involvement 4 (40 %) 3 (17.65%) 0.204
Laboratory ﬁndings
Serum amylase∗ 14.79 ±17.34 8.15 ±6.03 0.241
Serum lipase∗ 6.46 ±3.51 8.20 ±5.58 0.368
Elevated serum transaminase 8 (80%) 10 (58.82%) 0.244
Hypoalbuminemia 9 (90%) 8 (47.06%) 0.031
Proteinuria 10 (100%) 12 (70.59%) 0.077
Hematuria 10 (100%) 7 (41.18%) 0.002
Granular casts 7 (70%) 4 (23.53%) 0.024
Hyperbilirubinemia 4 (40%) 1 (5.88%) 0.047
Positive anti-dsDNA 10 (100%) 14 (82.35%) 0.232
Positive anti-Sm 2/8 (25%) 4/13 (30.77%) 0.59
Low C3 9/9 (100%) 17/17 (100%) 1.0
Low C4 7/9 (77.78%) 14/17 (82.35%) 0.58
Anti-Ro 3/8 (37.5%) 10/13 (76.92%) 0.09
Anti-La 1/8 (12.5%) 6/13 (46.15%) 0.133
∗Times in excess of the upper limit of normal (ULN).
37.04% compared to 0 in SLE patients without AP (P =
0.001), and mortality rate in SAP was 75%. The severity of
AP might be the most important risk factor for the mortality
of SLE-related AP patients (OR 11.25, 95% CI (1.611, 78.57),
and P = 0.014).
In accordance with other literatures, the manifestations
of SLE-related AP in this cohort were nonspeciﬁc and similar
to non-SLE acute pancreatitis. Abdominal pain (92.59%),
fever (77.78%), and nausea/vomiting (74.07%) were the
most common symptoms. These symptoms could also be
attributed to other gastrointestinal diseases or adverse reac-
tions of medication and may lead to misdiagnosis in general
practice.ItwasreportedthattherateofmisdiagnosisofAPin
SLE was up to 88.6% [31]. Delayed diagnosis and improper
treatment may contribute to unfavorable prognosis, even
lifethreatening [32]. Likewise, the mortality rate of the
Hopkins Lupus Cohort (3%) was considerably lower than
average of other reported studies due to close monitoring,
early diagnosis, and treatment [12]. So, AP should be paid
more attention in any SLE patient with abdominal pain
when mechanical obstruction or toxic-metabolic etiologies,
i n f e c t i o n ,o rt r a u m aw e r er u l e do u t .
Some immunosuppressants, such as corticosteroids, aza-
thioprine, and cyclosporine have been implicated to cause
pancreatitis in several case reports. Only 2 patients in our
studytookazathioprinebutthemedicationwasdiscontinued
after the onset of AP. The current study couldn’t verify
the relationship between azathioprine and acute pancreatitis
in SLE patients. There is still a controversy over steroid
treatment in SLE-related AP. Increasingly accumulated evi-
dence showed that steroids do not trigger acute pancreatitis
or cause increased mortality on AP [22, 33, 34], but
instead,theyhaveapossibletherapeuticeﬀectonSLE-related
pancreatitis [5, 35–37]. In Hopkins cohort, appropriate
treatment with corticosteroids added a survival beneﬁt in
SLE-related AP. In current study, 16 SLE-related AP patients
received intensive GC and/or ISA treatment, and 75% of
them exhibited favorable prognosis.
In summary, SLE-related acute pancreatitis is rare but
withhigh-mortality rate, whichis evenhigher in those severe
acute pancreatitis with multiple organ system involvement.
Activity of SLE, hematological system, renal, and liver injury
in SLE patients may attribute to the mortality of AP. Early
diagnosis of acute pancreatitis in SLE patients, especiallyClinical and Developmental Immunology 7
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Figure 2: Treatment regimen and outcome of the SLE-related AP.
those with abdominal pain, and appropriate glucocorti-
costeroid treatment is beneﬁcial for a better therapeutic
outcome in the majority of patients.
Abbreviations
AP: Acute pancreatitis
SAP: Severe acute pancreatitis
MAP: Mild acute pancreatitis
GC: Glucocorticosteroid
ISA: Immunosuppressive agents.
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